| Health / Medical Topics |
MVF-HER-2(628-647)-CRL 1005 Vaccine
A chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. HER-2 protein is a receptor tyrosine kinase and a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). Vaccination with this immunogen may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. (NCI Thesaurus)
YOU MAY ALSO LIKE
A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino…
A brand of cryofreezers designed to store samples in liquid nitrogen or vapor phase liquid nitrogen.
A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder cancer.
A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate…
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with…
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic…
